Drug profile · INN
denosumab-adet
PONLIMSI
denosumab-adet (PONLIMSI) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — denosumab-adet
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
denosumab-adet (PONLIMSI) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is denosumab-adet?
denosumab-adet (PONLIMSI) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for denosumab-adet?
PONLIMSI is a marketed brand name for denosumab-adet. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of denosumab-adet?
denosumab-adet has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.